Owing to limitations to face-to-face learning events as a result of the COVID- 19 pandemic, Pfizer aims to support enduring online educational programs designed to enhance healthcare practitioner (HCP) knowledge and understanding of the etiology, diagnosis, treatment, and management of patients with axial spondyloarthritis and/or psoriatic arthritis in clinical practice.
American Association for Cancer Research & The Mark Foundation for Cancer Research—”Science of the Patient” (SOP) Grants
The AACR-The Mark Foundation for Cancer Research “Science of the Patient” (SOP) Grants Program represents a joint effort to stimulate novel research aimed at understanding the influence of the biology of the host (i.e., patient) on the genesis, development, treatment, and survivorship of cancer.
Projects that will be considered for Pfizer support will focus on increasing awareness of the role of nuclear scintigraphy (inclusive of Tc- 99m PYP, Tc-99m DPD and Tc-99m HDMP) in the diagnostic work up of patients with suspected cardiac amyloidosis along with other multimodality imaging techniques
Through this RFP it is Pfizer's intent to support educational projects that focus on improving the care of patients with AD by increasing patient and caregiver knowledge of the disease state, preventative measures, and emerging strategies for treatment of AD. Of particular interest are:
The Glaucoma Research Foundation supports new high-impact clinical, epidemiological and laboratory research based on their strategic research goals.
The PhRMA Foundation seeks transformative, multi-stakeholder-driven solutions to address challenges in assessing the value of medicines and health care services to improve patient outcomes and reduce inefficiency.
Research projects that will be considered for Pfizer support will advance the medical knowledge of acromegaly disease, its complications and treatment with pegvisomant.
The mission of the Foundation is to support early stage investigators engaged in basic biomedical research that has the potential to significantly advance the understanding, diagnosis or treatment of disease. Any domestic biomedical institution, whether solely research or educational, is invited to submit one candidate for the Mallinckrodt Board's consideration.
Research projects that will be considered for Pfizer support will advance the medical knowledge of pediatric growth hormone deficiency. Projects submitted may include:
Applications must address clinical (hospital or outpatient) or community-related aspects of COVID-19.
Applications must address clinical (hospital or outpatient) or community-related aspects of COVID-19 that focus on an underrepresented minority (URM) patient group.
Through this RFP, it is Pfizer’s intent to support educational programs that address knowledge gaps for health care providers with the most recent pneumococcal immunization recommendations as described in the updated recommendations of the Advisory Committee on Immunization Practices.
Pfizer & Lilly—2020 Osteoarthritis and Osteoarthritis Pain- Virtual Learning Competitive Grant Program
Through this RFP, it is Pfizer’s intent to support virtual programs for HCPs on Osteoarthritis and Chronic Pain associated with OA patient-centered standard of care and management including pain and function, the biopsychosocial aspects of the disease, the complexities and challenges of care, and the future of OA/OA pain management. Programs targeted towards reviewing data from canceled or virtual rheumatology, pain, primary care or other associated medical conferences are of particular interest.
Through this RFP, it is Pfizer’s intent to support programs for dermatologists on new and emerging therapies for moderate-to-severe atopic dermatitis. All educational formats can be included in this RFP, but there is a particular interest in programs held in conjunction with dermatology-focused conferences such as the AAD Annual Meeting.
This is a competitive review process that will be conducted by the SARS CoV-2/COVID-19 MISP Review Committee. Decisions will be made on the basis of scientific merit and strategic fit within the AOI. Please review the critical activities and abide by the timelines as outlined below.
BrightFocus provides research funds for U.S. domestic as well as international researchers pursuing pioneering research leading to greater understanding, prevention, and treatment of age-related macular degeneration.
The Chan Zuckerberg Initiative invites applications for five-year grants to support the work of Imaging Scientists employed in imaging core facilities at non-profit universities or research institutes across the world.
Orthopaedic Research and Education Foundation—Multimodal Musculoskeletal Perioperative Pain Management Grant
Solicits investigator-initiated research proposals focused on the broad area of perioperative musculoskeletal pain management focused on, but not limited to the following areas:
Promotes the development of new clinician scientists who have demonstrated success as both a clinician and a researcher. Allows investigators to spend dedicated time in research for a period of up to five years to develop a long and productive career in academic surgery. Supplements the salary of an orthopaedic researcher that has secured an NIH K08 or K23 award from the NIH (or equivalent mentored research funding).
Projects that will be considered for Pfizer support will focus on Artificial Intelligence/Machine Learning in the areas mentioned below. Projects with a focus on emerging potential one-time treatments such as genetic medicine/gene transfer will be preferentially considered.